
Opinion|Videos|July 12, 2024
Where Does Axatilimab Fit in the Treatment Lineup?
Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What were the key findings from the AGAVE-201 trial presented at the 2023 ASH meeting?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















